Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Share-based Compensation (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Share-based Compensation for 7 consecutive years, with $9.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation rose 6.79% to $9.1 million in Q4 2025 year-over-year; TTM through Nov 2025 was $38.0 million, a 11.9% increase, with the full-year FY2025 number at $38.0 million, up 11.9% from a year prior.
  • Share-based Compensation was $9.1 million for Q4 2025 at Nurix Therapeutics, down from $9.8 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $10.4 million in Q2 2025 to a low of $2.7 million in Q1 2021.
  • A 5-year average of $7.5 million and a median of $8.4 million in 2022 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: skyrocketed 1434.09% in 2021, then decreased 7.77% in 2024.
  • Nurix Therapeutics' Share-based Compensation stood at $4.8 million in 2021, then skyrocketed by 71.32% to $8.3 million in 2022, then dropped by 3.29% to $8.0 million in 2023, then rose by 6.03% to $8.5 million in 2024, then rose by 6.79% to $9.1 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Share-based Compensation are $9.1 million (Q4 2025), $9.8 million (Q3 2025), and $10.4 million (Q2 2025).